Marker Therapeutics, Inc. on November 3, 2025 announced that data from the Phase 1 APOLLO study will be presented in two posters at the 67thAmerican Society of Hematology (ASH) Annual Meeting and Exposition, to be held from December 6-9, 2025, in Orlando, Florida. The Phase 1 APOLLO study (identifier: NCT05798897) is a multicenter, open-label trial investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with B cell lymphomas. Among patients with Non-Hodgkin lymphoma (NHL), including those who relapsed after anti-CD19 directed CAR-T cell therapy, the objective response rate (ORR) was 66% (8 out of 12) with 50% achieving a complete response (CR).
Responses were durable, ranging from 3 to 24 months, with five patients remaining in remission for 6 months or longer, including three patients with responses exceeding 12 months. In Hodgkin lymphoma (HL), the ORR was 78% (7 out of 9), with 11% achieving a CR. MT-601 was well tolerated by all study participants, with no reported dose limiting toxicities or ICANS.
Only two participants experienced Grade 1 cytokine release syndrome (CRS) (fever; no treatment was required).
